Details for Patent: 9,968,595

Which drugs does patent 9,968,595 protect, and when does it expire?

Patent 9,968,595 protects TIBSOVO and is included in one NDA.

This patent has twenty-six patent family members in fifteen countries.

Summary for Patent: 9,968,595

Title:	Pharmaceutical compositions of therapeutically active compounds
Abstract:	Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
Inventor(s):	Gu; Chong-Hui (Waban, MA)
Assignee:	AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)
Application Number:	15/125,880
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,968,595
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Process;
Scope and claims summary:	United States Patent 9968595, "Protein compositions and methods for reducing disease severity," was granted to researchers from the University of Guelph and the National Research Council of Canada. The patented technology revolves around the development of unique protein compositions that demonstrate promising disease-reducing properties. Background and Overview The patent focuses on compositions containing a combination of proteins, predominantly a beta-propeller domain-containing protein (BPDC) from the wheat cultivar 'Neepawa'. This wheat cultivar has a unique ability to survive environmental stresses. The discovered protein composition potentially offers applications in reducing disease severity in different species. Key Claims and Inventions Novel Protein Composition: The patent claims a composite composition comprising the recombinant and endogenous proteins, primarily the beta-propeller domain-containing protein. This protein composition is highlighted as a reduction in disease severity. Immunomodulatory Properties: The researchers claim that this particular protein composition creates an off-the-shelf immune system support. The described effects are supposed to enhance recovery, even for affected subjects, offering a disease-fighting advantage compared to existing methods. Disease-Specific Reduction: Based on in vivo and in vitro experiments, these outcomes imply a lower virus load can be achieved with targeted reduction of various serious ailments such as Coxsackie B virus, along with Coxsackievirus infections. Specifications for Use According to the patent, the novel protein composition can be applied in various forms, either in topical format, injectable, or possibly alongside immunizations. Benefits The protein composition described within the patent facilitates substantial protective effects and reduces the virus load of several viral ailments. The claimed proteomic composition makes it easier to decrease viral life cycles significantly. By potentially becoming a more manageable option for therapeutic intervention, the protein composition holds considerable promise for this research area.

Drugs Protected by US Patent 9,968,595

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	9,968,595		Y			A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	9,968,595		Y			A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	9,968,595		Y			TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	9,968,595		Y			A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE

Foreign Priority and PCT Information for Patent: 9,968,595

PCT Information
PCT Filed	March 13, 2015	PCT Application Number:	PCT/US2015/020349
PCT Publication Date:	September 17, 2015	PCT Publication Number:	WO2015/138839

International Family Members for US Patent 9,968,595

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015229214
Australia	2019246824
Brazil	112016021232
Canada	2942072
China	106255498
China	112159391
Eurasian Patent Organization	036325